131 related articles for article (PubMed ID: 26823114)
1. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
[TBL] [Abstract][Full Text] [Related]
2. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
5. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
6. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
7. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
[TBL] [Abstract][Full Text] [Related]
9. Cost of skeletal complications from bone metastases in six European countries.
Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
[TBL] [Abstract][Full Text] [Related]
10. Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Li N; Hao Y; Koo V; Fang A; Peeples M; Kageleiry A; Wu EQ; Guérin A
J Med Econ; 2016; 19(4):414-23. PubMed ID: 27032967
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of toxicities associated with treating metastatic melanoma in eight countries.
Wehler E; Zhao Z; Pinar Bilir S; Munakata J; Barber B
Eur J Health Econ; 2017 Jan; 18(1):49-58. PubMed ID: 26721505
[TBL] [Abstract][Full Text] [Related]
12. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
13. Patient reported burden of asthma on resource use and productivity across 11 countries in Europe.
Fletcher M; Jha A; Dunlop W; Heron L; Wolfram V; Van der Molen T; Price D
Adv Ther; 2015 Apr; 32(4):370-80. PubMed ID: 25913218
[TBL] [Abstract][Full Text] [Related]
14. Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines.
Buja A; Sartor G; Scioni M; Vecchiato A; Bolzan M; Rebba V; Sileni VC; Palozzo AC; Montesco M; Del Fiore P; Baldo V; Rossi CR
Acta Derm Venereol; 2018 Feb; 98(2):218-224. PubMed ID: 29110018
[TBL] [Abstract][Full Text] [Related]
15. End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study.
Gallais Sérézal I; Beaussant Y; Rochigneux P; Tournigand C; Aubry R; Lindelöf B; Morin L
Br J Dermatol; 2016 Sep; 175(3):583-92. PubMed ID: 27038100
[TBL] [Abstract][Full Text] [Related]
16. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
Goldstein DA; Zeichner SB
Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
[TBL] [Abstract][Full Text] [Related]
17. Melanoma treatment costs: a systematic review of the literature, 1990-2011.
Guy GP; Ekwueme DU; Tangka FK; Richardson LC
Am J Prev Med; 2012 Nov; 43(5):537-45. PubMed ID: 23079178
[TBL] [Abstract][Full Text] [Related]
18. Societal costs of home and hospital end-of-life care for palliative care patients in Ontario, Canada.
Yu M; Guerriere DN; Coyte PC
Health Soc Care Community; 2015 Nov; 23(6):605-18. PubMed ID: 25443659
[TBL] [Abstract][Full Text] [Related]
19. Melanoma prognosis in Europe: far from equal.
Forsea AM; Del Marmol V; Stratigos A; Geller AC
Br J Dermatol; 2014 Jul; 171(1):179-82. PubMed ID: 24588115
[TBL] [Abstract][Full Text] [Related]
20. Management of primary cutaneous and metastatic melanoma.
Rubin KM
Semin Oncol Nurs; 2013 Aug; 29(3):195-205. PubMed ID: 23958217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]